analyzing

Analyzing Token Sale Models

Source Node:
Time Stamp: February 20, 2024 1:29 PM - Modified On: February 20, 2024 - Published By:
Source Cluster:
Republished By Plato

Note: I mention the names of various projects below only to compare and contrast their token sale mechanisms; this should NOT be taken as an endorsement or criticism of any specific project as a whole. It's entirely possible for any given project to be total trash as a whole and yet still have an awesome token sale model. The last few months have seen an increasing amount of innovation in token sale models. Two years ago, the space was simple: there were capped sales, which sold a fixed number of

HealthCare AI: The Unavoidable Revolution in Modern Medicine

Source Node:
Time Stamp: October 5, 2023 3:40 PM - Modified On: October 5, 2023 - Published By:
Source Cluster:
Republished By Plato

By Eric Greenberg www.linkedin.com/in/ericabg In the evolving landscape of medical technology, there's one force that stands head and shoulders above the rest, promising a seismic shift in the very ethos of healthcare delivery: Artificial Intelligence (AI). As a seasoned technology and banking analyst, it is my considered opinion that Healthcare AI isn't just a trend or a buzzword. It’s the very future of medicine, poised to reshape everything we know about patient care, disease diagnosis, and medical research. To begin with, the economic implications of integrating AI in healthcare are

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo

Source Node:
Time Stamp: October 5, 2023 11:22 AM - Modified On: October 5, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo Clinical trials, the linchpin of medical research, have long been riddled with inefficiencies, from patient recruitment bottlenecks to data management hurdles. As a technology and banking analyst, I've seen how digital solutions can overhaul entire sectors, offering improved productivity and streamlined processes. It's high time that clinical trials get a dose of such digital innovation, and there's a potent combination on the horizon: digital watermarking coupled with Artificial Intelligence (AI). At first glance, one might wonder: how can a technique often

Verseon Acquires Edammo to Deepen Drug Discovery Approach

Source Node:
Time Stamp: November 13, 2022 3:46 AM - Modified On: November 17, 2022 - Published By:
Source Cluster:
Republished By Plato

Published: Nov 12th, 2022 | By Mark Terry Verseon Corporation has acquired Edammo, an artificial intelligence-focused company, to deepen its own AI-based drug discovery platform, the companies revealed Tuesday. Adityo Prakash, co-founder and CEO of Verseon and Ed Ratner, CEO at Edammo, discussed the acquisition with BioSpace. “We develop completely new drugs on the computer, atom by atom, then we make them in the laboratory,” Prakash said. "We’re changing how small molecule drugs are designed and developed with a level of efficiency that hasn’t been possible before.” He added that